May 17, 2013
/PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) is scheduled to participate in Digestive Disease Week (DDW®) 2013,
, Fla. More than 24 clinical presentations will feature new data and analyses on products including the Boston Scientific SpyGlass® Direct Visualization System, WallFlex® Biliary RX Stent System and Expect® 19 Flex Endoscopic Ultrasound Aspiration Needle.
"The insights and data included in these presentations further demonstrate the commitment of Boston Scientific to provide value to healthcare professionals and patients," said David Pierce, president, Endoscopy, Boston Scientific. "As we continue to evaluate and improve our broad portfolio for the diagnosis and treatment of gastrointestinal diseases, we look forward to continuing to collaborate with healthcare professionals to provide breakthrough innovations designed to enhance patient lives."
The SpyGlass Direct Visualization System, WallFlex Stents and Expect 19 Flex Needle will be available for demonstration at the Boston Scientific booth, #1549, throughout DDW. The company will also offer hands-on product demonstration sessions in its Simulated Clinical Endoscopy Suites and at its booth stations for GI Stents, Core Biliary, Visualization and Therapeutics for ERCP, Hemostasis, Dilation, Tissue Acquisition and Enteral Access. For more information on Boston Scientific endoscopy products, visit
Schedule of Key Podium and Poster Presentations (partial listing)
Poster presentations are scheduled from 8:00 a.m. to 5:00 p.m. ET at the Orange County Convention Center in Hall West A1. All clinical data results are under embargo until the start of each scientific presentation and 8:00 a.m. for poster presentations.
Saturday, May 18
- Endoscopic Placement of Self-Expanding Metal Stent for Gastric Outlet Obstruction Treatment: Data from a Large Series of Patients Roberto Di Mitri, M.D., will present results of a study to evaluate the efficacy and safety of self-expanding metal stent (SEMS) placement in a large consecutive series of patients with malignant inoperable gastroduodenal obstruction. The findings will be presented during a poster session. Abstract# SA1598
Sunday, May 19
- Changing Trends in Tissue Acquisition in Pancreatic Diseases Shyam Varadarajulu, M.D., will present results of a study which compared the frequency of use, hospital costs and variation in practice patterns between endoscopic ultrasound (EUS), percutaneous and surgical techniques for tissue acquisition in pancreatic diseases. The findings will be presented during a topic forum on Saturday from 4:30p.m. to 4:45p.m. in Room 109A. Abstract# 196
- Partially Covered Nitinol Versus Partially Covered Steel Self-Expandable Metal Stent in the Palliative Treatment of Malignant Distal Biliary Obstruction: Final Results from a Prospective, Randomized Multicenter Trial Farshad Frozanpor, M.D., will present results from a prospective, randomized, multicenter trial which evaluated stent patency, survival and complications after endoscopically-placed SEMS in patients with distal non-resectable malignant bile duct obstruction. Patients were randomized to receive a partially covered WallFlex Stent or WALLSTENT®. The findings will be presented during a topic forum from 8:15a.m. to 8:30a.m. in room 308D. Abstract# 288
- Choledocholithiasis Refractory to Conventional Endoscopic Extraction: Treatment with SPYGLASS-Guided Holmium LASER Lithotripsy Dimitrios Xinopoulos, M.D., will present results from a study which assessed the efficacy and safety of SpyGlass-assisted intracorporeal laser lithotripsy for difficult-to-treat biliary stones. The findings will be presented during a poster session. Abstract# SU1415
Monday, May 20
- Stent Removability and Mid-Term Stricture Resolution After Multi-Month Metal Stenting of Benign Biliary Strictures: Interim Report From an International Prospective Trial in 187 Patients  Guido Costamagna, M.D., will present interim results of this prospective trial to determine removability and long-term effectiveness of fully-covered self-expanding metal stents (FCSEMS) for treatment of benign biliary strictures. The findings will be presented during a poster session. Abstract# SU1430
- Diagnostic Value of SPYGLASS for Pancreatoscopy in the Diagnosis of Intraductal Papillary Mucinous Neoplasm of the Pancreas (IPMN) Emiri Kita, M.D., will present results from a study which evaluated the clinical value of the SpyGlass System to aid physicians in the diagnosis of IPMNs. The findings will be presented during a poster session. Abstract# MO1470
Tuesday, May 21
- Meta-Analysis Comparing Rates of Complications Between the Standard 19G and 22G/25G Needles for EUS-Guided FNA of Pancreatic Lesions Shyam Varadarajulu, M.D., will present results of a meta-analysis which compared the rates of complications between the standard 19G and 22G/25G needles for EUS-guided fine needle aspiration (FNA) of pancreatic lesions. The findings will be presented during a poster session. Abstract# MO1501
- Colonic Stents as Bridge to Elective Surgery Versus Emergency Surgery for Left Sided Malignant Colonic Obstruction – A Meta-Analysis of Randomized Controlled Trials Naga Swetha Samji, M.D., will present results of a meta-analysis of randomized controlled trials to compare the efficacy and safety of colonic stents as a bridge to elective surgery compared to emergency surgery in patients with malignant left-sided colonic obstruction. The findings will be presented during a poster session. Abstract# TU1527
Digestive Disease Week® (DDW®) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place
– 21, 2013, at the
The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at
About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit
and connect on
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, clinical trials and the importance of their results, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A –
in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A –
in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.